Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

NCT04579757 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT04579757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04579757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Lead sponsor
Hutchmed
Phase
Phase 1/2
Overall status
Terminated
Start date
March 5, 2021
Completion date
August 27, 2024
Enrollment
87 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid cancer, colorectal cancer, gastric cancer, metastatic solid tumor, neuroendocrine tumors, small cell lung cancer, soft tissue sarcoma